Cornblatt joins Nutramax Labs’ consumer division team
EDGEWOOD, Md. Nutramax Labs on Wednesday announced the addition of Brian Cornblatt to their consumer division team.
“Dr. Cornblatt comes to Nutramax Laboratories during a time of growth and expansion,” stated Troy Henderson, VP corporate operations and professional services at Nutramax. “The addition of Dr. Cornblatt to the Nutramax Laboratories team will further ensure the quality, innovation, and research for which Nutramax Laboratories is known in the industry.”
Cornblatt joined Nutramax Labs to collaborate with manufacturing, development and quality groups to bring new products to market and support those products post-launch. In addition, Cornblatt will collaborate with research and development departments in identifying, planning and summarizing laboratory and clinical studies for Nutramax Laboratories products into publishing and marketing pieces.
“The need for non-toxic and naturally-derived agents that have broad application at promoting health is great,” Cornblatt said. “At Nutramax Laboratories there is an impressive and unique commitment to an in-house research program that focuses on uncovering the scientific rationale for how their products work while ensuring overall product quality and safety.”
A Hopkins graduate with a PhD in pharmacology and molecular sciences and a post doctoral fellowship in environmental health sciences/toxicology, Cornblatt has been engaged in medical research for two decades, Nutramax stated.
Vitamin K may reduce risk of non-Hodgkin’s lymphoma
WASHINGTON In the first study of vitamin K and non-Hodgkin’s lymphoma risk, researchers at the Mayo Clinic campus in Minnesota have found that people who have higher intakes of vitamin K from their diet have a lower risk of developing non-Hodgkin’s lymphoma.
“These results are provocative, since they are the first work we have done on the connection between vitamin K and non-Hodgkin’s lymphoma, and this is a fairly strong protective effect,” stated the study’s lead investigator, James Cerhan, a cancer epidemiologist. “However, as with all new findings, this will need to be replicated in other studies.”
Non-Hodgkin’s lymphoma is a cancer of the immune system and is the most common hematologic malignancy in the United States.
Researchers at the Mayo Comprehensive Cancer Center are studying the connection between diet and non-Hodgkin’s lymphoma risk, and they became interested in a potential role for vitamin K. While vitamin K is best known for its essential function in several proteins involved in blood clotting (the name of the vitamin is derived from the German word “Koagulations”), it also appears to be important in other biological processes, including inhibition of inflammatory cytokines thought to play a role in non-Hodgkin’s lymphoma, as well as pathways involved in cell cycle arrest and cell death.
At the 101st Annual Meeting of the American Association for Cancer Research, researchers reported that the risk of developing non-Hodgkin’s lymphoma was approximately 45% lower for participants who had vitamin K intakes in the top quartile of intake in the study (more than 108 ug/day), compared to participants who had intakes in the bottom quartile (less than 39 ug/day). This association remained after accounting for other factors such as age, sex, education, obesity, smoking, alcohol use and intake of foods with high amounts of antioxidants.
The Mayo study enrolled 603 patients who were newly diagnosed with non-Hodgkin’s lymphoma as well as 1,007 matched cancer-free “control” participants. Researchers asked the participants to answer a food questionnaire about their usual intake of over 120 food items two years prior to their cancer diagnosis or enrollment into the study (controls). They also asked about use of a variety of supplements. Vitamin K intake was estimated from this data.
While there was a clear trend showing that a greater intake of vitamin K from dietary sources was associated with a lower risk of non-Hodgkin’s lymphoma, the use of vitamin K supplements presented a slightly different picture. Increasing intake of vitamin K from supplements did protect against non-Hodgkin’s lymphoma, but reached a point where the highest intake offered no reduction in risk. “The significance of this finding is unclear,” Cerhan said, “but suggests that taking high doses of supplements is unlikely to be helpful.” Cerhan also noted that people taking certain oral anticoagulants or seizure medications should closely follow their physician’s dietary recommendations with respect to vitamin K intake, since vitamin K can interfere with these drugs.
“Whether the protective effect we observed is due to vitamin K intake, or some other dietary or lifestyle exposure, cannot be definitely assessed in this study,” Cerhan said. “But these findings add to a lot of other data that support a diet that includes plenty of green leafy vegetables in order to prevent many cancers as well as other diseases.”
The study was funded by the National Cancer Institute.
BASF, OrganoBalance to commercialize probiotic to improve oral health
FLORHAM PARK, N.J. BASF earlier this month announced plans to commercialize the oral-friendly probiotic pro-t-action in collaboration with OrganoBalance.
“Working closely with OrganoBalance, we have been able to identify the L. paracasei strain that effectively and exclusively binds to the caries bacteria and in doing so improves elimination from the mouth,” stated Markus Pompejus, senior manager BASF Future Business. “The effectiveness of the active ingredients combined with BASF’s ability to offer a product ready for incorporation into everyday oral care products, truly represents new and exciting possibilities in the way of significantly improving oral health.”
Based on probiotic microorganisms, the active ingredient in pro-t-action binds to and eliminates bacteria from the mouth. The Berlin-based OrganoBalance is specialized in microbial strain development and microbiological screening.
Together the companies identified a very particular strain of Lactobacillus paracasei and BASF has since developed a proprietary production process enabling the active ingredient to be easily integrated into everyday consumer products like toothpaste, mouthwash, candies, lozenges and chewing gums used for daily oral care.
Bacteria in the oral cavity, such as Streptococcus mutans, initiate the onset of tooth decay converting the sugar from food into acids. These acids ultimately destroy tooth enamel, reducing essential minerals protecting the teeth and thus lead to lesions or cavities. Shown in testing, the active ingredient, L. paracasei, in pro-t-action has the ability to target the bacteria and bind exclusively to them. The bacteria can then be flushed out of the oral cavity by normal swallowing or rinsing. Needing to remain in the oral cavity for only a minimum of ten seconds to become active, pro-t-action is tasteless, odorless, pH-neutral and helps to maintain the healthy and beneficial microflora in the oral cavity.
Research on L. paracasei for the development of pro-t-action was conducted as a joint effort by OrganoBalance and BASF, in collaboration with the School of Dental Medicine at the University of Connecticut Health Center. The findings of the research, led by Jason Tanzer, University of Connecticut Health Center, and those of Christine Lang, OrganoBalance, was presented before the International Association of Dental Research annual conference held in Miami April 1 to 4.